Huntington's disease is an autosomal dominant condition with a progressive neurological phenotype, chorea, dystonia, disorganized cognitive decline, and behavioural problems. Huntington disease is a rare neurological illness with a prevalence of 2.7 per 100,000 persons globally. Usually, a parent with Huntington's disease who possesses a mutation in the Huntingtin gene passes it on to their children (HTT). However, new mutations account for up to 10% of instances. Before the age of 20, up to 10% of those with the gene mutation experience symptoms, while between 4 and 11% experience them beyond the age of 60. The progression of HD cannot be slowed down or stopped by treatment. Effective disease progression biomarkers to evaluate therapeutic interventions are required because there are presently no commercially accessible medications that can successfully prevent the illness, decrease its development, or delay its start. However, disease-modifying treatments may show promise for the future. The urgent need is to discover HD inhibitors. In this review article we have tried to find some natural compounds those maybe potential inhibitors for this rare neurodegenerative disease using molecular docking software Autodock Vina; and the natural substance Withania somnifera exhibited promising molecular docking studies, making it a viable inhibitor for Huntington's disease.